nyu medical grand rounds clinical vignette rachel shur pgy-2 october 16, 2012 u nited s tates d...

Post on 04-Jan-2016

219 Views

Category:

Documents

2 Downloads

Preview:

Click to see full reader

TRANSCRIPT

NYU Medical Grand Rounds Clinical Vignette

Rachel ShurPGY-2

October 16, 2012

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

• 56 woman who presented with 2 weeks of right foot numbness and weakness

Chief Complaint

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

•The patient was in her usual state of good health until approximately 1 month prior to presentation when she started experiencing intermittent headaches with associated nausea and vomiting. •Headaches became more frequent, occurring almost daily, worse in the morning•2 weeks prior to presentation, pt noted right foot numbness and weakness.•Presented to NYU after she had difficulty driving with her right foot.

History of Present Illness

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Additional History

•Past Medical History:•Gastroesophageal reflux disease

•Past Surgical History:•none

•Social History:•Lived with husband and 2 children, worked as real estate agent•No smoking or drug use, drank 2 glasses of wine per week

•Family History:•No family history of cancer or heart disease

•Allergies: •No Known Drug Allergies

•Medications:•Omeprazole 20mg daily

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Physical Examination

•General: anxious, well appearing, no acute distress•Vital Signs: T: 97.8ºF BP:133/86 HR: 87 RR:14 and O2 sat: 99% on room air•Right foot: decreased sensation to light touch and pin prick on anterior and posterior aspect up to ankle, 4/5 strength on flexion and extension•Remainder of Physical Exam was normal

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Laboratory Findings

•CBC: Hemoglobin 11.8 gm/dL / Hematocrit 34.2%

•Remainder of CBC was within normal limits

•Basic Metabolic panel: within normal limits

•Hepatic panel: within normal limits

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Other Studies

•CT and MRI brain revealed frontal lobe masses with edema and mass effect, but no herniation

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

• The working diagnosis at this time was Gliobastoma Multiforme (GBM)

Working Diagnosis

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

• Hospital Day 3:– Pt underwent resection of the right sided

lesion (pathology was consistent with glioblastoma multiforme)

• Hospital Day 10:– Pt developed deep vein thrombosis and was

started on Lovenox/Coumadin

Hospital Course

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Hospital Course

• Pre and post contrast MRI obtained 1 week post craniotomy revealed post-operative changes +/- residual tumor

• Pt was discharged on Hospital Day 15

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Hospital Course

• Within one month of surgery, she started focal external beam radiation therapy with concurrent temozolomide chemotherapy for a six week course (6480 cGy).

• Post radiation MRI revealed increased surrounding edema.

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• The patient completed 6 cycles of adjuvant temozolomide prior to having progression of disease.

• She then had once cycle of BCNU chemotherapy complicated by anemia requiring transfusion.

• She was offered participation in a clinical trial with bevacizumab, after an IVC filter was placed and coumadin was discontinued.

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• She had a dramatic response to bevacizumab therapy, maintained for 6 cycles.

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• A new lesion was detected, but additional treatment had to be interrupted in order to place a ventriculoperintoneal shunt for communicating hydrocephalus.

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• The patient had further treatment delays for shunt related complications and intractable seizures. She was treated with enzyme-inducing antiepileptic drugs (EIAEDs).

• She developed clinical and radiographic progression of disease.

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• Since her tumor over-expressed epidermal growth factor receptor (EGFR) and intact phosphate and tensin homolog gene (PTEN), she was treated with erlotinib despite being on EIAEDs.

• There was no response to erlotinib and she died several months later of progressive disease (~18 months from initial hospital admission).

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

Disease Course

• Gliobastoma multiforme

Final Diagnosis

UNITED STATES

DEPARTMENT OF VETERANS

AFFAIRS

top related